Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)
McClung, A. Lombardi, José Zanchetta(Universidad del Salvador), KD Kaufman, Xi Ling, Tomomi Nakamura(Mie University), J Walliser, C. Roux, Jean‐Yves Reginster(King Saud University), HG Bone, Rachid Massaad(MSD (Belgium)), A. Rybak-Feiglin, C.F. Zerbini, Kurt Lippuner(University of Bern), Socrates E. Papapoulos(Leiden University Medical Center), N Verburggen, CA DaSilva, Bente Langdahl(Aarhus University Hospital), Dosinda Cohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), A.C. Santora, IR Reid, SK Lim, DP Kiel, KG Saag, P Kumar Km, T. de Villiers, Albert Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. Adámi, BB Scott, Awc Kung(University of Hong Kong), C. Mautalén, N B Watts, A Rodriguez-Portales
Open Repository and Bibliography (University of Liège)
January 1, 2015
Cited by 3
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k